Multiple myeloma

Active Research Protocols

  1. 00-C-0201 – Active Immunization of Sibling Stem Cell Transplant Donors Against Purified Myeloma Protein of the Stem Cell Recipient with Multiple Myeloma in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation
  2. 03-C-0077 – A Pilot Study of EPOCH-F/R Induction Chemotherapy and Reduced-Intensity, HLA-Matched, Related Allogeneic Hematopoietic Stem Cell Transplantation, with Cyclosporine & Methotrexate GVHD Prophylaxis for Refractory or Relapsed Hematologic Malignancies
  3. 03-C-0124 – Follow-Up Study of Breast Cancer and Multiple Myeloma Subjects Previously Enrolled in Retroviral Gene Transfer Studies
  4. 04-C-0055 – Allogeneic HSCT without Preparative Chemotherapy or with Low-Intensity Preparative Chemotherapy using Sirolimus and Sirolimus-Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome
  5. 06-H-0248 – Peripheral Blood Stem Cell Allotransplantation for Hematological Malignancies Using a Positive Stem Cell Selection Technique for T Cell Depletion, Followed by Delayed T Cell Add-Back
  6. 07-C-0195 – Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders
  7. 07-H-0136 – Selective Depletion of Alloreacting T Cells Using a Photodepletion Technique to Prevent GVHD after HLA-Matched Peripheral Blood Stem Cell Transplantation for Subjects with Hematologic Malignancies
  8. 09-C-0224 – Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
  9. 09-H-0094 – A Pilot Study of the Safety and Efficacy of Escalating Doses of ON 01910.Na in Patients with Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
  10. 09-I-0200 – A Phase I Study of Mozobil (TM) in the Treatment of Patients with WHIMS
  11. 10-C-0079 – A Phase 2 Study of AZD6244 in Multiple Myeloma
  12. 11-C-0016 – Multi-Center Phase I Study of Th1/Tc1 Immunotheraphy Following Autologous Hematopoietic Progenitor Cell Transplantation in High Risk Multiple Myeloma
  13. 11-C-0020 – A Pilot Study of Novel Imaging Modalities in Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), and Multiple Myeloma (MM)
  14. 11-C-0024 – A Phase II Trial of IPH2101 (Anti-KIR) in Smoldering Multiple Myeloma (SMM)
  15. 11-C-0221 – Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study
  16. 11-C-0232 – A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination with mTOR Inhibitor RAD001 (Everolimus) in Patients with Relapsed Multiple Myeloma or Lymphoma
  17. 12-C-0043 – Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients with Relapsed and Refractory Disease
  18. 12-C-0074 – Mobilization and Collection of Autologous Stem Cell for Transplantation (ASCT) for Plasma Cell Myeloma (PCM)
  19. 12-C-0106 – Novel Imaging Modalities to Characterize Angiogenesis in the Bone Marrow Microenvironment in Multiple Myeloma (MM) and its Precursor Disease
  20. 12-C-0107 – Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: A Clinical and Correlative Study
  21. 12-C-0169 – Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
  22. 12-C-0179 – Phase I / II Study Of Carfilzomib (CFZ) Intensification Early After Autologous Transplantation (AHCT) For Plasma Cell Myeloma
  23. 12-C-0180 – MLN9708 and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
  24. 12-C-0192 – Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study
  25. 12-C-0193 – Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol
  26. 13-H-0144 – Peripheral Blood Stem Cell Allotransplantation For Hematological Malignancies Using Ex Vivo CD34 Selection - a Platform For Adoptive Cellular Therapies
  27. 97-H-0099 – HLA-Matched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T Cell Add-Back for Hematological Malignancies
  28. 97-H-0202 – Low Intensity Preparative Regimen Followed by HLA-Matched, Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in Older Adults
  29. 99-C-0143 – Pilot Study of Donor Th2 Cells for the Prevention of Graft-Versus-Host Disease in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation
  30. 99-H-0046 – Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T-Cell Add-Back for Hematological Malignancies - Role of Cyclosporine
  31. 99-H-0050 – Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients with Debilitating Hematologic Diseases
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014